Despite tremendous scientific progress, stunning clinical results, and a slew of commercial approvals, this paradigm shifting industry finds itself facing an increasingly oppressive macro-economic climate. Public and private investment in CGT is trending downwards to decade lows. Pipelines and workforces are being slashed at increasing rates. Input costs are expected to rise as world leaders erect trade barriers and protectionist policies putting more pressure on supply chains and balance sheets.